Piper Sandler’s analyst David Westenberg upgrades Cytek Biosciences, Inc. (NASDAQ:CTKB) from “Hold” to “Buy” with a price target of $12, indicating confidence in the company’s future performance.
Cytek reports a 7% increase in revenue year-over-year in Q3 2024, driven by strong international demand and a 25% surge in service revenue.
The company achieved earnings of $0.01 per share in Q3 2024, surpassing the Zacks Consensus Estimate of a $0.02 loss per share, showcasing its improving financial health.
Cytek Biosciences, Inc. (NASDAQ:CTKB) is a company that focuses on providing advanced cell analysis solutions. Their flagship products, the Aurora and Northern Lights systems, are spectrum flow cytometers that enhance cell analysis capabilities. Cytek also offers a variety of reagents, kits, and automated systems to support these tools, making them a key player in the biomedical research and clinical applications market.
The consensus price target for Cytek’s stock has seen a decline over the past year, dropping from $6.88 to $5.25. This change suggests a shift in analyst expectations. However, Piper Sandler’s analyst David Westenberg has upgraded Cytek from “Hold” to “Buy” and set a price target of $12, reflecting confidence in the company’s future performance. This upgrade is based on Cytek’s improving financials and strong demand for its products.
Cytek’s financial performance has shown positive trends, with a 7% increase in revenue year-over-year in Q3 2024, driven by international demand. Service revenue also surged by 25% year-over-year, enhancing the company’s recurring revenue streams. Despite these positive developments, a recently announced buyback plan has gone largely unnoticed, which could be a factor in the stock’s price target adjustments.
In its Q3 2024 earnings report, Cytek achieved earnings of $0.01 per share, surpassing the Zacks Consensus Estimate of a $0.02 loss per share. This performance is consistent with the same period last year. However, in Q2 2024, Cytek reported a quarterly loss of $0.08 per share, which was below the Zacks Consensus Estimate of a $0.03 loss per share, indicating some volatility in its financial performance.
Cytek’s share price increased by 5.1% in the last trading session, with above-average trading volume. Despite this positive movement, the trend in earnings estimate revisions does not indicate sustained strength in the near future. However, Cytek is highlighted as a standout opportunity in the lab instrument and services sector due to its robust growth and manageable losses, as noted by Piper Sandler’s analyst David Westenberg.
